Drugs Containing Excipient (Inactive Ingredient) APRICOT KERNEL OIL PEG-6 ESTERS

« Back to Dashboard

Generic drugs containing APRICOT KERNEL OIL PEG-6 ESTERS excipient

Company	Ingredient	NDC	Excipient
Walgreens	miconazole nitrate	0363-0730	APRICOT KERNEL OIL PEG-6 ESTERS
Actavis Pharma Inc	miconazole nitrate	0472-0730	APRICOT KERNEL OIL PEG-6 ESTERS
Major Pharmaceuticals	miconazole nitrate	0904-7734	APRICOT KERNEL OIL PEG-6 ESTERS
Rite Aid Corporation	miconazole nitrate	11822-0730	APRICOT KERNEL OIL PEG-6 ESTERS
Aidarex Pharmaceuticals LLC	econazole nitrate	33261-956	APRICOT KERNEL OIL PEG-6 ESTERS

Apricot Kernel Oil PEG-6 Esters Market Dynamics and Financial Trajectory

Last updated: September 25, 2026

Apricot kernel oil PEG-6 esters is a niche nonionic surfactant and emollient used primarily in topical, cosmetic, and formulation applications. Its commercial value comes from solubilization, emulsification, skin feel, and compatibility with oil-in-water systems rather than from large-volume pharmaceutical demand. No standalone public revenue series, audited market valuation, Orange Book listing, or product-specific financial disclosure is available for the ingredient. The most defensible outlook is a specialty-ingredient growth profile with modest volume expansion, high supplier qualification requirements, and margin sensitivity to feedstock costs.

What is apricot kernel oil PEG-6 esters?

Apricot kernel oil PEG-6 esters is a polyethylene glycol derivative of apricot kernel oil. The ingredient is generally identified in cosmetics and formulation documentation as PEG-6 Apricot Kernel Oil or Apricot Kernel Oil PEG-6 Esters. It combines a vegetable-oil-derived lipophilic portion with polyethylene glycol functionality.

The ingredient is used for:

• Emulsification of oil and water phases
• Solubilization of fragrance, oils, and lipophilic actives
• Wetting and dispersion
• Emollience and skin conditioning
• Texture modification in creams, lotions, cleansers, and topical delivery systems

The material is not a single-molecule active pharmaceutical ingredient. Commercial grades can vary by raw-material source, degree of ethoxylation, free polyethylene glycol content, acid value, hydroxyl value, water content, residual solvents, and oxidation profile.

Attribute	Commercial relevance
Ingredient type	Nonionic surfactant, emulsifier, solubilizer, emollient
Raw-material base	Apricot kernel oil and polyethylene glycol
Primary dosage-form relevance	Topical, dermal, cosmetic, and personal-care products
Oral pharmaceutical relevance	Limited and product-specific
Sterile injectable relevance	Not a mainstream use
Main quality risks	Oxidation, residual impurities, batch variability, microbial contamination
Main cost drivers	Vegetable oil, ethoxylation, purification, testing, packaging, logistics
Regulatory position	Excipient or cosmetic ingredient, depending on use and jurisdiction

How large is the apricot kernel oil PEG-6 esters market?

No reliable public source reports a standalone global market size for apricot kernel oil PEG-6 esters. Market research companies generally aggregate it into broader categories such as nonionic surfactants, cosmetic emulsifiers, polyethylene glycol esters, specialty emollients, or pharmaceutical excipients.

Its addressable market is therefore best assessed through end-use exposure:

End market	Current commercial importance	Growth outlook
Skin-care and facial formulations	High	Moderate
Cleansing products	Moderate	Moderate
Pharmaceutical topical formulations	Moderate to low	Moderate to high from a small base
Oral lipid formulations	Low	Selective
Injectable formulations	Very low	Limited
Industrial applications	Low	Flat to modest
Custom formulation and contract manufacturing	Moderate	Moderate

The commercial market is likely fragmented. Product volumes are small relative to commodity surfactants, but qualification, regulatory documentation, and formulation performance can support higher unit margins. Demand is driven by formulation wins rather than broad substitution across large pharmaceutical portfolios.

What drives demand for apricot kernel oil PEG-6 esters?

Topical drug delivery and dermal formulations

Topical formulators seek excipients that improve spreading, solubilize oil-soluble ingredients, and produce acceptable sensory characteristics. Apricot kernel oil PEG-6 esters can be attractive where a formulation requires a plant-derived oil component combined with nonionic surfactant behavior.

Demand is strongest when the excipient performs multiple functions in one formulation. A material that acts as both an emollient and a solubilizer can reduce the number of formulation components and simplify product development.

Clean-label and plant-derived positioning

Apricot kernel oil provides a plant-derived origin that can support consumer-product positioning. That advantage is weaker in regulated pharmaceutical products, where consistency, impurity control, and supplier qualification carry more weight than marketing language.

The plant-derived origin also creates supply-chain exposure. Crop yield, geographic sourcing, oil quality, pesticide residues, and oxidation control can affect cost and availability.

Growth in specialty topical products

Dermatology, personal care, cosmeceuticals, and over-the-counter topical products are the most plausible growth channels. These products typically have shorter development cycles than prescription medicines and can adopt specialty excipients without the same level of clinical and regulatory burden.

Pharmaceutical adoption remains slower because sponsors must establish identity, specifications, supplier controls, and product-specific safety. FDA inactive-ingredient precedent depends on dosage form, route, and concentration. An ingredient appearing in one product does not automatically establish acceptability for every route or dosage form (U.S. Food and Drug Administration, 2024a).

What are the main supply-chain and manufacturing barriers?

Manufacturing is based on esterification or transesterification of apricot kernel oil-derived fatty materials with polyethylene glycol, followed by purification and specification control. Commercial performance depends on controlling the distribution of fatty-acid chains and ethoxylated species.

The main barriers are:

1. Raw-material consistency. Apricot kernel oil is a natural feedstock. Fatty-acid composition can vary by origin, cultivar, processing method, and season.
2. Oxidative stability. Unsaturated fatty acids can generate peroxides and secondary oxidation products during storage.
3. Residual impurities. Free oil, unreacted polyethylene glycol, catalysts, water, residual solvents, and low-molecular-weight species must be controlled.
4. Batch-to-batch sensory variation. Color, odor, viscosity, and spreadability can affect finished-product acceptance.
5. Pharmaceutical documentation. Drug sponsors may require detailed certificates of analysis, allergen statements, elemental impurity information, microbiological controls, change-control procedures, and traceability.
6. Dual-use supply chains. Suppliers serving cosmetics may not meet the documentation and quality expectations of pharmaceutical customers.

The qualification barrier is commercially important. Once a manufacturer validates an excipient in a regulated product, replacement can require stability work, comparability studies, and regulatory review. That creates retention value for incumbent suppliers.

What is the FDA and regulatory status of apricot kernel oil PEG-6 esters?

Apricot kernel oil PEG-6 esters is not a drug and does not receive FDA approval as an independent therapeutic product. Its regulatory treatment depends on its use in a finished product.

For a pharmaceutical product, the sponsor remains responsible for demonstrating that the excipient is suitable at the proposed concentration and route. Relevant documentation may include:

• Identity and composition
• Manufacturing process description
• Residual solvent controls
• Microbiological specifications
• Oxidation and stability data
• Toxicological support
• Supplier qualification
• Change-control commitments
• Finished-product compatibility

The FDA Inactive Ingredient Database can provide precedent where the precise ingredient, route, dosage form, and concentration are listed. Absence of a matching entry does not establish that the ingredient is prohibited, but it increases the sponsor’s documentation burden (U.S. Food and Drug Administration, 2024a).

The European Union assesses excipients through the finished medicinal product framework. The European Medicines Agency has published guidance on excipient quality, safety, and pharmaceutical justification, with specific attention to composition, manufacture, impurities, and toxicological information (European Medicines Agency, 2018).

In cosmetics, the ingredient is subject to jurisdiction-specific cosmetic ingredient rules and labeling requirements. The European Commission’s CosIng database provides regulatory and naming information but does not itself constitute an approval for a particular formulation or claim (European Commission, 2025).

What patents protect apricot kernel oil PEG-6 esters?

No Orange Book patent estate is associated with apricot kernel oil PEG-6 esters as an excipient. The ingredient is not an active drug and does not create a standalone pharmaceutical exclusivity period under the Hatch-Waxman framework.

Potential intellectual-property protection can instead arise from:

• Manufacturing processes
• Catalyst systems
• Narrow compositional ranges
• Purification methods
• Stabilization systems
• Specific topical or oral formulations
• Combination products
• Delivery systems using the excipient
• Trade secrets covering process conditions and quality controls

The most commercially relevant protection is likely know-how rather than a broad composition patent. Natural-oil PEG derivatives can be difficult to protect with broad claims because the underlying materials and general reaction concepts are known. Enforceability depends on whether a patent claims a specific composition or process that competitors cannot easily design around.

When does apricot kernel oil PEG-6 esters lose exclusivity?

The ingredient does not have a single exclusivity-loss date. It is not a branded drug with a defined patent expiry or regulatory exclusivity period.

Exclusivity is instead determined by:

Protection mechanism	Typical commercial effect
Composition patent	May restrict sale of a defined chemical mixture or specification
Process patent	May restrict a manufacturing route until expiry
Formulation patent	May protect a particular finished product
Trade secret	Can persist while confidential and commercially useful
Supplier qualification	Creates practical switching costs
Regulatory data	May delay or complicate competitor entry in some jurisdictions
Trademark or grade name	Protects branding, not the underlying ingredient

For finished pharmaceutical products, formulation or method-of-use patents may cover the product containing the excipient. Those rights belong to the drug sponsor and do not establish exclusivity over apricot kernel oil PEG-6 esters itself.

How strong is the competitive position of the ingredient?

The ingredient has moderate formulation differentiation but limited fundamental exclusivity. Its competitive position depends on performance, documentation, availability, and price.

Direct and adjacent competitors

Likely alternatives include:

• Other PEG-modified vegetable oils
• Polysorbates
• Sorbitan esters
• PEG glycerides
• Caprylocaproyl polyoxyl glycerides
• Polyglyceryl esters
• Phospholipids
• Synthetic or semi-synthetic emollient esters
• Alkoxylated fatty acids and fatty alcohols

Apricot kernel oil PEG-6 esters can win where formulators value plant-derived origin, emollience, and mild surfactant behavior. It can lose where the customer prioritizes pharmacopeial monographs, global supply depth, low peroxide levels, or established regulatory precedent.

Large specialty excipient suppliers such as BASF, Croda, Gattefossé, IOI Oleo, and Ashland compete across adjacent lipid, surfactant, and delivery-system categories. Competition is usually portfolio-based rather than centered on this single ingredient.

What is the financial trajectory for apricot kernel oil PEG-6 esters?

The most likely financial trajectory is steady specialty-market expansion without the revenue profile of a mass-market excipient.

Period	Expected commercial pattern
Near term	Stable demand from cosmetics and topical products; margin pressure from raw-material and logistics costs
Medium term	Selective growth from dermal delivery, clean-label products, and contract manufacturing
Longer term	Greater value from high-purity, low-oxidation, pharmaceutical-grade variants
Downside case	Substitution by standardized PEG esters, polysorbates, or lower-cost synthetic emulsifiers
Upside case	Adoption in multiple prescription topical or consumer-health platforms

Revenue quality is more important than volume. A supplier with a qualified pharmaceutical grade, global documentation, and reliable supply can earn stronger margins than a supplier selling an undifferentiated cosmetic grade.

The main financial risks are:

• Dependence on a small number of customers
• Crop and commodity volatility
• Customer substitution during reformulation
• Regulatory delays
• Product liability exposure
• Limited purchasing scale
• Costly quality-control testing
• Long qualification cycles in pharmaceuticals

Public-company financial statements generally do not report this ingredient separately. Revenue exposure must be estimated from the supplier’s broader excipient or personal-care portfolio, making precise market-share or profit estimates unreliable.

What generic entry risks exist for products containing this excipient?

The excipient itself does not create generic-entry risk. Generic risk applies to the finished drug product.

A generic sponsor may challenge:

• Formulation patents
• Process patents
• Method-of-use patents
• Device patents
• Stability or release-control claims
• Combination-product claims

A Paragraph IV certification would relate to listed patents for the finished drug, not to an Orange Book listing for apricot kernel oil PEG-6 esters. A generic manufacturer can often use a different excipient or source the same excipient from another supplier if the finished-product specification and regulatory requirements permit it.

The excipient can still create practical barriers when the branded product depends on a narrow formulation window, proprietary grade, or difficult-to-replicate stability profile. Those barriers are technical and commercial, not independent statutory exclusivity.

What licensing deals and litigation affect the ingredient?

No major publicly disclosed licensing transaction or high-profile patent litigation can be reliably attributed to apricot kernel oil PEG-6 esters as a standalone excipient. Commercial arrangements are more likely to involve:

• Private-label supply
• Regional distribution
• Contract manufacturing
• Technical-support agreements
• Finished-product formulation licenses
• Confidential development programs

Litigation risk is more likely to arise at the finished-product level or from supply and quality disputes than from direct infringement claims over the base excipient.

Key Takeaways

• Apricot kernel oil PEG-6 esters is a niche nonionic surfactant, solubilizer, emulsifier, and emollient.
• Cosmetics and topical formulations are the strongest current demand centers.
• Pharmaceutical growth is possible but constrained by quality documentation, route-specific safety, and supplier qualification.
• No standalone public market-size or revenue data supports a precise financial forecast.
• The ingredient has no Orange Book exclusivity and no single patent-expiry date.
• Competitive strength depends on formulation performance, supply reliability, oxidation control, and regulatory documentation.
• The strongest commercial opportunity is in higher-value pharmaceutical and dermal grades rather than commodity-volume applications.
• Generic-entry exposure belongs to finished products using the excipient, not to the excipient itself.

FAQs About Apricot Kernel Oil PEG-6 Esters

Is apricot kernel oil PEG-6 esters the same as PEG-6 caprylic/capric glycerides?

No. They are different PEG-modified lipid materials with different raw-material profiles and fatty-acid distributions. Substitution requires formulation and compatibility testing.

Can apricot kernel oil PEG-6 esters be used in oral medicines?

Potentially, but acceptability is product-specific. The sponsor must assess route, concentration, composition, impurities, safety, and regulatory precedent.

Is apricot kernel oil PEG-6 esters a natural ingredient?

It has a plant-derived oil component but is chemically modified through polyethylene glycol esterification. It should not be treated as an unmodified natural oil.

What quality tests are most important for this excipient?

Typical controls include identity, acid value, hydroxyl value, saponification value, peroxide value, water, viscosity, color, residual polyethylene glycol, microbial quality, and relevant elemental or process impurities.

Can a pharmaceutical company change the supplier after approval?

A supplier change may be possible, but it can require comparability data, stability studies, quality assessment, and regulatory notification or approval depending on the product, jurisdiction, and change classification.

References

European Commission. (2025). CosIng: Cosmetic ingredients database. European Commission.

European Medicines Agency. (2018). Guideline on the quality of water for pharmaceutical use and excipients in medicinal products. European Medicines Agency.

International Pharmaceutical Excipients Council. (2022). Good distribution practices for pharmaceutical excipients. IPEC.

U.S. Food and Drug Administration. (2024a). Inactive ingredient database. Center for Drug Evaluation and Research.

U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.